These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Abdul-Ghani MA; Norton L; DeFronzo RA Curr Diab Rep; 2012 Jun; 12(3):230-8. PubMed ID: 22528597 [TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Scheen AJ Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Chen LH; Leung PS Diabetes Obes Metab; 2013 May; 15(5):392-402. PubMed ID: 23331516 [TBL] [Abstract][Full Text] [Related]
5. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Abdul-Ghani MA; Norton L; Defronzo RA Endocr Rev; 2011 Aug; 32(4):515-31. PubMed ID: 21606218 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Fioretto P; Giaccari A; Sesti G Cardiovasc Diabetol; 2015 Oct; 14():142. PubMed ID: 26474563 [TBL] [Abstract][Full Text] [Related]
7. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes. Davidson JA; Kuritzky L Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933 [TBL] [Abstract][Full Text] [Related]
8. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. Levine MJ Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042 [TBL] [Abstract][Full Text] [Related]
9. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes. Whalen K; Miller S; Onge ES Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804 [TBL] [Abstract][Full Text] [Related]
10. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882 [TBL] [Abstract][Full Text] [Related]
11. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087 [TBL] [Abstract][Full Text] [Related]
12. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Krentz AJ; Bailey CJ Drugs; 2005; 65(3):385-411. PubMed ID: 15669880 [TBL] [Abstract][Full Text] [Related]
13. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Lajara R Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597 [TBL] [Abstract][Full Text] [Related]
14. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Abdul-Ghani MA; Norton L; DeFronzo RA Am J Physiol Renal Physiol; 2015 Dec; 309(11):F889-900. PubMed ID: 26354881 [TBL] [Abstract][Full Text] [Related]
15. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223 [TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Ferrannini E; Solini A Nat Rev Endocrinol; 2012 Feb; 8(8):495-502. PubMed ID: 22310849 [TBL] [Abstract][Full Text] [Related]
17. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Abdul-Ghani MA; DeFronzo RA; Norton L Diabetes; 2013 Oct; 62(10):3324-8. PubMed ID: 24065789 [TBL] [Abstract][Full Text] [Related]
18. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770 [TBL] [Abstract][Full Text] [Related]
19. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Vallon V Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005 [TBL] [Abstract][Full Text] [Related]
20. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors. Freeman JS Postgrad Med; 2013 May; 125(3):214-26. PubMed ID: 23748522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]